What medications should be combined with bedaquiline fumarate (Snaery)?

Bedaquiline fumarate (Bedaquiline) is often used as part of a combination treatment regimen to treat multidrug-resistant tuberculosis (MDR-TB ). Combining multiple anti-tuberculosis drugs can improve the success rate of treatment and reduce the occurrence of drug resistance. The following are common combination regimens of fumaric acidbedaquiline (Sneril) :

1.Isoniazid (INH): Isoniazid is an anti-tuberculosis drug widely used in the treatment of tuberculosis, usually as a first-line drug. It exerts its antibacterial effects by inhibiting cell wall synthesis of Mycobacterium tuberculosis. The effectiveness of treatment may be enhanced when combined with fumaric acidbedaquiline (Sneril).

2.Rifampicin (RFP): Rifampicin is a powerful anti-tuberculosis drug and one of the first-line drugs. It exerts its antibacterial effects by interfering with protein synthesis of Mycobacterium tuberculosis. Use in combination with fumaric acidbedaquiline (Sneril)to increase treatment coverage and success.

3.Ethambutol (EMB): Ethambutol is a commonly used anti-tuberculosis drug, often used in combination with other drugs. It exerts its antibacterial effects by inhibiting cell wall synthesis of Mycobacterium tuberculosis. The effectiveness of treatment may be enhanced when combined with fumaric acidbedaquiline (Sneril).

4.Delamanid (Delamanid): Delamanid is a new anti-tuberculosis drug that is also used to treat MDR-TB. Its use in combination with fumaric acidbedaquiline (Sneril)may increase the success rate of treatment and reduce the occurrence of drug resistance.

5.Alophenol (PZA): Alophenol is an anti-tuberculosis drug commonly used in first-line treatment regimens. It exerts its antimicrobial effect by interfering with the acid-base balance of Mycobacterium tuberculosis. Treatment coverage may be enhanced when combined with fumaric acidbedaquiline (Sneril).

In general, fumaric acid Bedaquiline (Sneril) is often used in combination with anti-tuberculosis drugs such as isoniazid, rifampicin, ethambutol, delamanid and alaminophen to construct a comprehensive treatment regimen, improve the success rate of treatment and reduce the occurrence of drug resistance. However, the specific combination drug regimen needs to be personalized and adjusted according to the patient's drug resistance, clinical manifestations and treatment response, and is formulated by the doctor based on the actual situation.